LOBEF - Lobe Sciences to collaborate for trial of psilocin compound L-130 to treat cluster headaches

• Lobe Sciences ( OTCQB:LOBEF ) said it had signed an investigator initiated research agreement with the Medical Director of Integrative Headache Medicine of New York to study the tolerability and efficacy of psilocin compound L-130, in patients suffering from Cluster Headaches.
• "Since L-130 is the active metabolite of psilocybin, it appears to be an efficient way of delivering non-psychedelic doses of psilocin with potentially better bioavailability and consistency," said Founder and Medical Director of Integrative Headache Medicine of New York  Lauren Natbony.

For further details see: